Neogap receives Chinese patent for tumour-specific T cell expansion technology
Neogap Therapeutics AB has been granted Chinese patent protecting its proprietary method for expanding tumour-specific T cells, marking a significant milestone in the company’s international intellectual property strategy. The patent, which provides legal protection until 2038, covers a core manufacturing process for the company’s personalised cell-based immunotherapy, pTTL, currently under evaluation in Phase I/II clinical trials for advanced colorectal cancer.
The granted patent protects an ex vivo expansion method that exposes tumour-specific T cells to selected antigens, enabling the production of therapeutic cell populations with enhanced tumour reactivity. This technique forms an integral component of Neogap’s proprietary EpiTCer® technology platform, which works in conjunction with the PIOR® software system to identify and multiply T cells capable of recognising and attacking tumour-specific targets.
Strategic positioning in key market
China represents one of the world’s largest and fastest-growing life science markets, making this patent grant particularly significant for Neogap’s commercial strategy. The protection complements an equivalent European patent granted in 2023 and other intellectual property approvals across key markets, establishing a coordinated international framework for the company’s core technologies.
“Strong international IP protection is critical as we advance in clinical development – not only to enable future partnerships, but to reinforce the global credibility of our technology,” said Samuel Svensson, chief executive officer of Neogap Therapeutics.
Clinical development progress
The pTTL therapy combines sophisticated DNA sequencing with T cell expansion to deliver personalised precision cancer treatment. The approach utilises PIOR software to analyse DNA sequencing data through machine learning algorithms, identifying tumour-specific mutations before EpiTCer technology multiplies reactive T cells. The therapy has received classification as an Advanced Therapy Medicinal Product from the European Medicines Agency, supporting its regulatory pathway in European markets. The Stockholm-based company, located at Cancer Center Karolinska, continues to evaluate pTTL in ongoing clinical trials whilst expanding its intellectual property protection across global markets.
For more information, visit: https://neogap.se
